Clinical Trial: NCT02819596
MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Queen Mary University of London |
| Information Provided By: | Queen Mary University of London |
| Last Update Posted: | 2024-11-04 |
Study Overview
Brief Summary
This study is being carried out to see if the drugs MEDI4736, Savolitinib and Tremelimumab can be used alone or in combination to reduce the size of tumours in patients with kidney cancer.
The drugs being tested in this study have an anti-tumour effect and have been tested in pre-clinical and human studies before. MEDI4736 and tremelimumab work with the immune system to help the body fight against tumour cells with immune cells. Savolitinib works to correct a faulty signal which causes tumour growth.
If a patient is eligible for the study and decides to take part, they will be enrolled into one of 3 stages of the study.
- First stage [CLOSED TO RECRUITMENT]: aims to find the optimal dose of MEDI4736+savolitinib.
- Second stage [CLOSED TO RECRUITMENT]: patients with papillary cell cancer will be treated with MEDI4736+savolitinib. Patients with clear cell cancer will be randomised to one of four treatment arms and receive MEDI4736, savolitinib, MEDI4736+savolitinib, or MEDI4736+tremelimumab.
- Third stage [NOT YET OPEN TO RECRUITMENT]: patients will be tested for biomarkers before enrolment, and depending on the results will be allocated to one of 2 treatments (MEDI4736 alone or MEDI4736+tremelimumab) to see if certain biomarkers are linked to drug efficacy.
Official Title
Conditions
Intervention / Treatment
- Drug: Savolitinib
- Drug: MEDI4736
- Drug: Tremelimumab
Other Study ID Numbers
- 010580QM
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Queen Mary University of London |
| Information Provided By: | Queen Mary University of London |
| Last Update Posted: | 2024-11-04 |
Study Overview
Brief Summary
This study is being carried out to see if the drugs MEDI4736, Savolitinib and Tremelimumab can be used alone or in combination to reduce the size of tumours in patients with kidney cancer.
The drugs being tested in this study have an anti-tumour effect and have been tested in pre-clinical and human studies before. MEDI4736 and tremelimumab work with the immune system to help the body fight against tumour cells with immune cells. Savolitinib works to correct a faulty signal which causes tumour growth.
If a patient is eligible for the study and decides to take part, they will be enrolled into one of 3 stages of the study.
- First stage [CLOSED TO RECRUITMENT]: aims to find the optimal dose of MEDI4736+savolitinib.
- Second stage [CLOSED TO RECRUITMENT]: patients with papillary cell cancer will be treated with MEDI4736+savolitinib. Patients with clear cell cancer will be randomised to one of four treatment arms and receive MEDI4736, savolitinib, MEDI4736+savolitinib, or MEDI4736+tremelimumab.
- Third stage [NOT YET OPEN TO RECRUITMENT]: patients will be tested for biomarkers before enrolment, and depending on the results will be allocated to one of 2 treatments (MEDI4736 alone or MEDI4736+tremelimumab) to see if certain biomarkers are linked to drug efficacy.
Official Title
Conditions
Intervention / Treatment
- Drug: Savolitinib
- Drug: MEDI4736
- Drug: Tremelimumab
Other Study ID Numbers
- 010580QM